Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma

Journal of Orthopaedic Research

Volumn 32, Issue 5, 2014, Pages 695-701

  Duan, Zhenfeng ^a   Shen, Jacson ^a   Yang, Xiaoqian ^a   Yang, Pei ^a   Osaka, Eiji ^a   Choy, Edwin ^a   Cote, Gregory ^a   Harmon, David ^a   Zhang, Yu ^b   Nielsen, G Petur ^a   Spentzos, Dimitrios ^c   Mankin, Henry ^a   Hornicek, Francis ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Liuhuaqiao Hospital   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

chordoma; Met; miR 1; prognostic biomarker

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BIOLOGICAL MARKER; MICRORNA 1;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CELL GROWTH; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CHONDROMA; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; VERY ELDERLY;

CHORDOMA; MET; MIR-1; PROGNOSTIC BIOMARKER;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CHORDOMA; DOWN-REGULATION; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TUMOR MARKERS, BIOLOGICAL;

EID: 84899437390     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22589     Document Type: Article

References (33)

1. Bydon M, Papadimitriou K, Witham T, et al. 2012. Novel therapeutic targets in chordoma. Expert Opin Ther Targets 16: 1139-1143.
2. Walcott BP, Nahed BV, Mohyeldin A, et al. 2012. Chordoma: current concepts, management, and future directions. Lancet Oncol 13: e69-e76.
3. DeLaney TF, Duan Z, Hornicek FJ,. 2010. Proteomic profiling of chordoma. J Surg Oncol 102: 719.
4. Diaz RJ, Cusimano MD,. 2011. The biological basis for modern treatment of chordoma. J Neurooncol 104: 411-422.
5. Yang C, Schwab JH, Schoenfeld AJ, et al. 2009. A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther 8: 2597-2605.
6. Di Leva G, Garofalo M, Croce CM,. 2013. MicroRNAs in cancer. Annu Rev Pathol 9: 287-314.
7. Kobayashi E, Hornicek FJ, Duan Z,. 2012. MicroRNA involvement in osteosarcoma. Sarcoma 2012: 359739.
8. Kong YW, Ferland-McCollough D, Jackson TJ, et al. 2012. microRNAs in cancer management. Lancet Oncol 13: e249-e258.
9. Holleman A, Chung I, Olsen RR, et al. 2011. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 30: 4386-4398.
10. Croce CM,. 2009. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714.
11. Duan Z, Choy E, Nielsen GP, et al. 2010. Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J Orthop Res 28: 746-752.
12. Yan D, Dong Xda E, Chen X, et al. 2009. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 284: 29596-29604.
13. Migliore C, Martin V, Leoni VP, et al. 2012. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res 18: 737-747.
14. Reid JF, Sokolova V, Zoni E, et al. 2012. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res 10: 504-515.
15. Fleming JL, Gable DL, Samadzadeh-Tarighat S, et al. 2013. Differential expression of miR-1, a putative tumor suppressing microRNA, in cancer resistant and cancer susceptible mice. Peer J 1: e68.
16. Novello C, Pazzaglia L, Cingolani C, et al. 2013. miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol 42: 667-675.
17. Hudson RS, Yi M, Esposito D, et al. 2012. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 40: 3689-3703.
18. Scheil S, Bruderlein S, Liehr T, et al. 2001. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32: 203-211.
19. Liu X, Nielsen GP, Rosenberg AE, et al. 2012. Establishment and characterization of a novel chordoma cell line: CH22. J Orthop Res 30: 1666-1673.
20. Ryan BM, Robles AI, Harris CC,. 2010. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10: 389-402.
21. Subramanian S, Lui WO, Lee CH, et al. 2008. MicroRNA expression signature of human sarcomas. Oncogene 27: 2015-2026.
22. Palmieri A, Pezzetti F, Graziano A, et al. 2008. Comparison between osteoblasts derived from human dental pulp stem cells and osteosarcoma cell lines. Cell Biol Int 32: 733-738.
23. Duan Z, Choy E, Harmon D, et al. 2011. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther 10: 1337-1345.
24. Zhang L, Guo S, Schwab JH, et al. 2013. Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma. PLoS ONE 8: e75851.
25. Long C, Jiang L, Wei F, et al. 2013. Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas. PLoS ONE 8: e66676.
26. Bayrak OF, Gulluoglu S, Aydemir E, et al. 2013. MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. J Neurooncol 115: 143-151.
27. Hu Z, Chen X, Zhao Y, et al. 2010. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28: 1721-1726.
28. Nasser MW, Datta J, Nuovo G, et al. 2008. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 283: 33394-33405.
29. Tominaga E, Yuasa K, Shimazaki S, et al. 2013. MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties. Exp Cell Res 319: 77-88.
30. Datta J, Kutay H, Nasser MW, et al. 2008. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 68: 5049-5058.
31. Wang F, Song G, Liu M, et al. 2011. miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. FEBS Lett 585: 3263-3269.
32. Gherardi E, Birchmeier W, Birchmeier C, et al. 2012. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12: 89-103.
33. Patel A, Tiwari AK, Chufan EE, et al. 2013. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemother Pharmacol.